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Genetic and biochemical evidence points to an association
between mitochondrial dysfunction and Parkinson’s disease
(PD). PD-associated mutations in several genes have been iden-
tified and include those encoding PTEN-induced putative
kinase 1 (PINK1) and parkin. To identify genes, pathways, and
pharmacological targets that modulate the clearance of dam-
aged or old mitochondria (mitophagy), here we developed a
high-content imaging-based assay of parkin recruitment to
mitochondria and screened both a druggable genome-wide
siRNA library and a small neuroactive compound library. We
used a multiparameter principal component analysis and an
unbiased parameter-agnostic machine-learning approach to
analyze the siRNA-based screening data. The hits identified in
this analysis included specific genes of the ubiquitin proteasome
system, and inhibition of ubiquitin-conjugating enzyme 2 N
(UBE2N) with a specific antagonist, Bay 11-7082, indicated that
UBE2N modulates parkin recruitment and downstream events
in the mitophagy pathway. Screening of the compound library
identified kenpaullone, an inhibitor of cyclin-dependent ki-
nases and glycogen synthase kinase 3, as a modulator of parkin
recruitment. Validation studies revealed that kenpaullone aug-
ments the mitochondrial network and protects against the com-
plex I inhibitor MPP. Finally, we used a microfluidics platform
to assess the timing of parkin recruitment to depolarized mito-
chondria and its modulation by kenpaullone in real time and
with single-cell resolution. We demonstrate that the high-con-
tent imaging-based assay presented here is suitable for both
genetic and pharmacological screening approaches, and we also
provide evidence that pharmacological compounds modulate
PINK1-dependent parkin recruitment.
Parkinson’s disease (PD)2 is the second most common neu-
rodegenerative disease and is characterized by the degeneration
of midbrain dopaminergic (DA) neurons. Historic biochemical
research suggested that interlinked pathways, governing free-
radical production, iron metabolism, and mitochondrial func-
tion were altered in PD. Genetic and molecular evidence has
since confirmed an association between mitochondrial dys-
function and PD (1–3). In rare familial cases of PD, causal muta-
tions in a number of coding genes have been identified and
include PTEN-induced putative kinase 1 (PINK1), parkin
(PRKN), -synuclein (SNCA), leucine-rich repeat kinase 2
(LRRK2), ATPase 13A2 (ATP13A2), VPS35 (PARK17), and Par-
kinsonism-associated deglycase (PARK7)/DJ-1 (4). Functional
dissection of these genes found that systems governing mito-
chondrial quality control, the ubiquitin proteasome system,
and protein trafficking and clearance through the autophago-
somal-lysosomal network are involved in the etiology of PD (5).
Mitochondrial dysfunction, possibly due to mutations in mito-
chondrial DNA, has also been shown to increase the risk of
developing PD and other late onset human diseases, such as
multiple sclerosis and Rett syndrome (6 –8). In addition, expo-
sure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its
active metabolite 1-methyl-4-phenylpyridinium (MPP)
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inhibits mitochondrial respiratory complex I in DA neurons
and leads to a form of Parkinsonism (9). Furthermore, the
risk of developing PD is increased by exposure to pesticides,
such as rotenone, that also affect mitochondrial respiratory
complex I (10).
Mitochondria are exceptionally dynamic organelles; they
undergo continuous rounds of biogenesis, fusion, fission, and
removal to ensure that the cell has a population capable of
meeting its metabolic demands. A key event in this life cycle is
the decision to clear old/damaged mitochondria by the selec-
tive use of the macroautophagic process termed mitophagy. In
healthy mitochondria, which maintain a normal membrane
potential, PINK1 is recruited to and rapidly transported across
the outer mitochondrial membrane (OMM) to the inter mem-
brane space, where it is cleaved by proteases, including mito-
chondrial processing peptidase and presenilin-associated
rhomboid-like (11, 12). When mitochondria become depolar-
ized (e.g. due to oxidative phosphorylation inhibition, depolar-
izing agents, mitochondrial DNA mutations, or disease) PINK1
cannot be imported, and it accumulates on the OMM (13, 14).
Mitochondrial proteins are constitutively ubiquitinated by E3
ligases such as MITOL (membrane-associated ring-CH-type
finger 5; MARCH5). Accumulated PINK1 phosphorylates the
ubiquitin chains and triggers parkin recruitment (15). Subse-
quently, parkin is phosphorylated by PINK1, resulting in the
activation of its E3 ligase activity (16 –19). Activated parkin
leads to further ubiquitination of mitochondrial proteins in a
positive feedback cycle and so signals the mitochondrion for
autophagic degradation via recruitment of autophagy adapters,
such as sequestosome 1 (SQSTM1/p62) and microtubule-asso-
ciated protein 1 light chain 3 /microtubule-associated protein
1 light chain 3  2 (MAP1LC3A/B2). We employed a pheno-
typic assay based on parkin recruitment to identify genes and
compounds that modulate this pathway (20 –23). To focus on
disease-relevant targets, we screened a druggable-genome
siRNA library (targeting 7500 genes) and used multiparametric
analysis and a parameter-agnostic machine-learning approach
to maximize the identification of hits and key nodes that drive
parkin recruitment. Second, we screened a library of neuroac-
tive compounds to identify modulators of mitophagy and thus
potential therapeutic options.
We validated hits from both screens by investigating effects
on (i) the downstream ubiquitination and degradation of OMM
proteins; (ii) the mitochondrial network; and (iii) the ability to
protect against the mitochondrial toxin MPP. Furthermore,
we established a microfluidics/microscopy-based assay to
monitor parkin recruitment in real time. Together, we show
how combining multiple screening approaches can aid the dis-
covery of targetable master regulators of mitophagy and help
the identification of pharmacological strategies that promote
mitochondrial function and present new therapeutic options
for PD.
Results
We established an assay of parkin recruitment that was suit-
able for high-throughput screening. EGFP-tagged parkin
(EGFP-PRKN) was used to visualize parkin translocation to the
mitochondria following treatment with the protonophore car-
bonyl cyanide 3-chlorophenylhydrazone (CCCP) to dissipate
m (Fig. S1, A and B). In addition, MitoTracker Red and EGFP-
PRKN puncta showed a nearly complete colocalization follow-
ing treatment with CCCP (Fig. S1A). Cells transfected with a
nontargeting control (NTC) siRNA showed robust recruitment
of parkin to the mitochondria and peri-nuclear clustering of
parkin-tagged mitochondria, whereas siPINK1-transfected
cells showed no recruitment of EGFP-PRKN, and mitochondria
remained distributed throughout the cytoplasm (Fig. 1A). The
images were segmented to identify and quantify nuclei
(Nucleus), cell bodies (Cell), and parkin puncta (Organelle) (see
“Experimental procedures” for details; Fig. 1B). Initial experi-
ments in which EGFP-PRKN and siRNA were co-transfected
showed heterogeneity in the level of EGFP-PRKN expression,
resulting in poor reproducibility and suboptimal assay windows
between positive (siPINK1) and negative (NTC) controls (Fig.
S2, A and B), and a stable EGFP-PRKN cell line was therefore
made (Fig. S3). The concentration and duration of CCCP treat-
ment was then optimized to ensure a robust assay window
allowing detection of both positive and negative modulators of
mitophagy (Fig. S4). A primary screen using the Dharmacon
OnTarget Plus druggable genome (7514 genes) Smartpool (4
siRNAs/gene) siRNA library was carried out using our
H4-EGFP-PRKN cells (Fig. 1C) together with NTC (negative
control) and PINK1-targeting (siPINK1) (positive control)
siRNAs included on all plates (Fig. 1D). All plates were trans-
fected and assayed in triplicate. 48 h post-transfection, cells
were stained with MitoTracker Red CMXRos (100 nM, 1 h) and
treated with CCCP (10 M, 2 h) prior to being fixed, and the
nuclei were labeled with Hoechst.
After quality control, 6138 genes were carried forward to the
hit selection stage, where we used the principal components
analysis (PCA) workflow (see “Experimental procedures”) to
score the genes (Fig. 1E). The distribution of the values follows
a cumulative normal distribution (Fig. 1F). Setting a PCA score
cut-off of either 3 or 3, a collection of 333 genes were
identified as hits within the primary screen (File S1). The hits of
this list showed a statistically significant enrichment for previ-
ously reported parkin interactors (24) (see “Parkin interactor
enrichment”) with a p value of 0.0058.
To validate the results of the primary screen and control for
off-target effects, the top 300 hits from the primary screen were
carried forward to a secondary screen (Fig. 2). For this, we had a
custom library of Ambion Silencer Select siRNAs synthesized
consisting of three individual siRNAs per gene (File S2).
H4-EGFP-PRKN cells were assayed in the same manner as for
the primary screen with the exception that the siRNA concen-
tration of the single siRNAs was reduced to 0.25 pmol/well, and
all plates were run with n  6. In addition, the positioning of
NTC and siPINK1 controls were adjusted to better control for
row and column effects (Fig. 2A). Analysis of the data using the
PCA score (for the three previously identified key parameters)
revealed that the PRKN puncta/cell intensity parameter poorly
separated the NTC from PINK1 controls. As a PCA score value
based on two parameters is suboptimal, a parameter-agnostic
machine-learning approach (partial least squares; PLS) was
taken to analyze the data to identify phenotypic hits (Fig. 2B)
(for a full description, see “PLS workflow”). Analysis of the data
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based on this PLS score revealed that a significantly strong
effect (SSMD  1.3 or SSMD  1.3) could only be found for
all three secondary screen siRNAs in the same direction as the
significant change for the smart pool in the primary screen for
three genes, but there were 22 gene hits where this effect was
found in two of three siRNAs and 55 genes where this effect was
found in one of three siRNAs (see last column in File S3). To
identify the most significant and robust hits, the gene SSMD
values from both the primary and secondary screens were com-
bined in the form of a weighted score (File S3). As the different
quality numbers, corresponding to the different studies, are not
comparable with each other, this field contains the mean value
Figure 1. Screening of the druggable genome library. A, overlay of example images captured by the InCell Analyzer of H4-EGFP-PRKN cells stained with
MitoTracker Red and Hoechst following 2-h CCCP treatment. B, example of images captured by the InCell Analyzer and the segmentation of nuclei (blue), cells
(green), and EGFP-PRKN puncta (Organelles) (yellow). C, schematic of mitophagy assay, image capture, and quantification workflow. D, 96-well plate layout
showing the position of NTC and siPINK1 wells. E, PCA analysis pipeline. F, PCA score data showing thresholds of 3 and 3. Scale bars, 50 m.
Figure 2. Secondary screen analysis pipeline and results. A, 96-well plate layout showing the position of NTC and siPINK1 wells. B, schematic of the analysis
pipeline for the secondary screen. C, STRING analysis showing the interactions (known and predicted) between the hit genes identified in the secondary PRKN
screen and the cellular pathways controlled by these gene clusters. Width of edge denotes confidence of interaction.
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of all of the normalized PCA and PLS measures (i.e. normalized
to their respective absolute maximum value). This is only pos-
sible as both the SSMD and the PCA measures correspond to
their actual effect measures (and are not just significance mea-
sures as in the case of p values). As the weighted score is com-
puted through the mean, genes showing opposite behaviors
were penalized across all of the different studies and methods.
To select genes for further analysis, we carried forward the top
10% positive and 10% negative regulating genes based on this
weighted score (corresponding to a weighted score of 0.637
or 0.6880), which resulted in a total of 58 genes (top 29 and
bottom 29 genes from the summary table in File S3). Gene
ontology analysis of these 58 genes revealed that there was an
enrichment for “cellular metabolic process” and “organic sub-
stance metabolic process,” whereas PANTHER pathway analy-
sis revealed enrichment for “ubiquitin proteasome pathway”
(25). Similarly, STRING database analysis (Fig. 2C) revealed
clusters of genes involved in ubiquitination, proteasomal
degradation, control of oxidative stress (e.g. genes involved
in GSH biosynthesis, copper, and zinc metabolism), calcium
metabolism, cargo/organelle transport, and control of gene
expression (DNA binding/transcriptional regulation) (Fig.
2C) (26). We selected 16 genes (File S4) for further validation
according to a number of criteria, including (i) having a
known gene expression profile in H4 cells (see “Gene expres-
sion in H4 cells”); (ii) evidence of parkin binding (24); (iii)
general links to mitochondrial function and/or neurodegen-
eration; and (iv) occurrence of multiple hit genes within a
functional pathway as identified by STRING, gene ontology,
and PANTHER pathway analyses.
We used qPCR to determine whether the siRNAs used in the
secondary screen resulted in an effective knockdown of the cor-
responding target (Fig. S5). For 11 of 16 genes (ATP2B2, CIB2,
DPYSL2, GSTK1, HK2, PPARG, SLC31A1, UBE2E1, UBE2J2,
UBE2L6, and UBE2N), there were at least two siRNAs that
mediated a significant reduction in the target mRNA compared
with the NTC RNA. For two genes (GSR and TTBK1), it trans-
pired that only one siRNA sequence had been provided in the
library, and for four genes (CIB2, SLC31A1, UBE2E1, and
UBE2J2), only two sequences had been provided. GPX6 failed
to amplify under the reaction conditions used. The siRNAs
mediating the most robust knockdown of each target were used
in subsequent validation studies.
Due to the functional clustering of many of the hits, we
decided to investigate whether targeting multiple genes (within
a cluster) at the same time increased the observed effect on
parkin recruitment. One of the clusters included members of
the E2 ubiquitin-conjugating enzymes (UBE2s) whose activity
is required for the activation of E3 ubiquitin ligases (UBE3s) like
parkin. Of the four UBE2s identified, UBE2N and ubiquitin-
conjugating enzyme E2 J2 (UBE2J2) were shown to be positive
modulators of parkin recruitment (their knockdown reduced
parkin recruitment in the screen), and ubiquitin-conjugating
enzyme E2 L6 (UBE2L6) and ubiquitin-conjugating enzyme E2
E1 (UBE2E1) were shown to be negative regulators of parkin
recruitment (their knockdown increased parkin recruitment in
the screen). Co-transfection of siRNAs targeting UBE2N and
UBE2J2 mediated a statistically significant impairment in
CCCP-induced parkin recruitment compared with the controls
(siUBE2N  siUBE2J2 versus NTC, p  0.0001; Fig. 3 (A and
B)). The knockdown of UBE2N or UBE2J2 individually did not
result in a statistically significant impairment in parkin recruit-
ment as measured by the percentage of cells containing more
than three parkin puncta. The screen hits were identified using
the combined PCA and PLS analysis, a sensitive multiparamet-
ric method able to detect significant effects with low -fold
change, and this may explain the inability to detect significance
in this experiment. Targeting UBE2L6 and UBE2E1 alone or in
combination did not result in significantly altered parkin
recruitment when compared with the NTC. Subsequent inter-
rogation of the primary and secondary screen data showed that
there was a high degree of variation in the phenotypic measures
(e.g. the percentage of cells containing more than three parkin
puncta) (Fig. S6). This variation was particularly pronounced
for UBE2E1 and therefore explains the apparent discrepancy in
the data between initial screens and validation shown in Fig. 3B.
siRNA-mediated knockdown of the UBE2s in the absence of
CCCP had no effect on measures of parkin recruitment (data
not shown).
To further validate and interrogate the effect of E2 ligase
inhibition on parkin recruitment and mitophagy, we used Bay
11-7082 (27), a known pharmacological inhibitor of UBE2N.
Pretreating cells with Bay 11-7082 prior to CCCP challenge (in
the continued presence of Bay 11-7082) attenuated parkin
recruitment in a dose-dependent manner (FBay(3,16)  5.309,
p  0.01; Fig. 3 (C and D)). Combined siRNA-mediated
knockdown of UBE2N and pharmacological inhibition with
Bay 11-7082 showed no summative effect compared with Bay
11-7082 treatment alone, suggesting that the effect of Bay
11-7082 is mediated via inhibition of UBE2N and not one of its
other targets (Fig. S7). Together, these data provide further evi-
dence for the role of UBE2N in parkin-mediated mitophagy and
demonstrate for the first time that pharmacological targeting of
the ubiquitin pathway can be used to modulate mitophagy.
Ubiquitination and proteasomal degradation of OMM pro-
teins by parkin is a key step in the degradation of mitochondria
by mitophagy. This ubiquitination can be visualized by the
appearance of higher-molecular-weight protein bands on a
Western blot (Fig. 4, A and D) (28). We identified changes in the
ubiquitination and expression levels of the OMM proteins
TOMM70 and Ras homolog family member T2 (RHOT2/
Miro2) when cells were pretreated with Bay 11-7082 prior to
mitochondrial uncoupling with CCCP (Fig. 4). There was an
increase in the ratio of ubiquitinated to total TOMM70 (Fig. 4,
A and B) and RHOT2 (Fig. 4, D and E) following 2-h CCCP
treatment that was attenuated in the presence of Bay 11-7082;
similarly, there was a decrease in total protein expression of
TOMM70 in the presence of CCCP that again was attenuated
in the presence of Bay 11-7082, suggesting an impaired degra-
dation of the protein (Fig. 4C). Analysis of the total levels of
RHOT2 was less clear; there was a significant decrease in total
protein levels following CCCP treatment but no effect of Bay
11-7082 (Fig. 4, D and F). In a second approach to identifying
novel modulators of mitophagy and given the success of mod-
ulating this process with the compound Bay 11-7082, we con-
ducted a screen of a targeted compound library. We selected
Identifying novel gene and drug modulators of mitochondria














pharmacological compounds known to modulate the genes/
cellular pathways identified in our siRNA screen (oxidative
stress, proteasome) and neuroactive compounds that acted via
mechanisms relevant to neurodegeneration (ER stress, excito-
toxicity, Nrf2 activation, and ion channels) (File S5). For each of
the compounds chosen, there is strong evidence that they can
modulate the relevant pathways both in vitro and in vivo, and
several of the compounds are in clinical trials or in the clinic
(e.g. riluzole). H4-EGFP-PRKN cells were treated with 10 M
concentrations of the neuroactive compounds for 24 h prior to
the mitophagy assay (10 M CCCP, 2 h in the presence of com-
pound). Four compounds (GSK2606414, BIX, cu-ASTM, and
TRC 051384) reduced the cell number by more than 20% and
were therefore deemed toxic and excluded from further analy-
sis (Fig. S8A). The effects on parkin recruitment were quanti-
fied, as before, revealing a significant effect of compound
(F(22,224)  3.468, p  0.0001) (Fig. 5A). Post hoc tests showed
that kenpaullone, a cyclin-dependent kinase (CDK) and glyco-
gen synthase kinase 3 (GSK3) inhibitor, significantly reduced
the percentage of cells with more than three PRKN puncta (p 
0.001).
To validate this result, H4-EGFP-PRKN cells were treated
with increasing doses of kenpaullone and assayed for PRKN
recruitment (Fig. 5, B and C). Again, we observed a significant
impairment of parkin recruitment in the presence of kenpaul-
lone (Fken(2,55)  17.96, p  0.0001) (Fig. 5C) and no toxicity as
measured by cell count (Fig. S8B). The ability of kenpaullone to
modify parkin recruitment to mitochondria was also investi-
gated in EGFP-PRKN– expressing SH-SY5Y cells, a human
neuroblastoma cell line with a dopaminergic phenotype com-
monly used as a neuronal model. SH-SY5Y-EGFP-PRKN cells
showed CCCP-dependent PRKN recruitment to mitochondria
(Fig. 5D). We noted that the recruitment was slower than seen
in H4-EGFP-PRKN cells and that due to the tendency for indi-
vidual cells to form one or two large puncta, measures of the
total area or intensity of parkin puncta/cell gave a good readout,
Figure 3. UBE2N and UBE2J2 are positive modulators of PRKN recruitment. A, representative images of PRKN recruitment in H4-EGFP-PRKN cells trans-
fected with the indicated combinations of siRNAs and treated with CCCP (10 M, 2 h). B, quantification of PRKN recruitment as displayed in A; there was a
significant effect of siRNA (F(7,24)  77.84, p  0.0001), and post hoc tests revealed that simultaneous knockdown of UBE2N and UBE2J2 enhanced the
impairment of PRKN recruitment compared with knockdown of the individual genes (p  0.0001) (n  4). C, representative images of H4-EGFP-PRKN cells
treated with the UBE2N inhibitor Bay 11-7082 and CCCP (10 M, 2 h) as indicated. D, quantification of PRKN recruitment, as shown in C, identified a dose-de-
pendent inhibition of CCCP-induced PRKN recruitment by Bay 11-7082 (FBay(3,16)  5.309, p  0.01) (n  3). Scale bar, 50 m. Lines, mean  S.D. (error bars). *,
significant difference from NTC/vehicle control; #, significant difference between highlighted pair; #, p  0.05; ##, p  0.01; ***/###, p  0.001.
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Figure 5. Screening a neuroactive compound library identified kenpaullone as a modulator of PRKN recruitment. A, H4-EGFP-PRKN cells were treated
with the library compounds (10 M) for 24 h and then treated with CCCP (10 M, 2 h) to assay PRKN recruitment. Data show the percentage of cells with three
or more PRKN puncta (from four independent plates). Analysis revealed a significant effect of compound (F(22,224)  3.468, p  0.0001). Post hoc tests showed
that kenpaullone significantly reduced the percentage of cells with PRKN puncta (F(2,55)  17.96, p  0.001). B and C, H4-EGFP-PRKN cells were pretreated with
kenpaullone for 24 h, and CCCP-induced PRKN recruitment was assayed as before. B, representative images of EGFP-PRKN. C, analysis of three independent
plates revealed significant effects of kenpaullone and CCCP (Fken(3,25)  4.644, p  0.05; FCCCP(1,25)  89.52, p  0.0001; Finteraction(3,25)  4.708, p  0.01). D–G,
the effect of kenpaullone on PRKN recruitment was also investigated in SH-SY5Y-EGFP-PRKN cells. D, representative images showing EGFP-PRKN in cells
treated with kenpaullone and CCCP as indicated. E, treatment with kenpaullone did not change the mean number of parkin puncta per cell (Fken(3,168)  2.148,
p  0.1342). Total area of parkin puncta per cell (Fken(3,16)  3.451, p  0.05) (F) and intensity of parkin puncta (normalized to the background fluorescence in
each cell) (Fken(3,16)  19.55, p  0.0001) (G) are both significantly reduced in cells treated with 1–10 M kenpaullone compared with vehicle control (n  3
independent plates). E–G, all three measures of PRKN recruitment showed a significant effect of CCCP. Scale bar, 50 m. Lines, mean  S.D. (error bars). *,
significant difference between vehicle and CCCP; #, significant effect of kenpaullone between highlighted pair; *, p  0.05; **/##, p  0.01; ***/###, p  0.001.
Figure 4. Pharmacological inhibition of UBE2N modulates ubiquitination of OMM proteins following CCCP-induced PRKN recruitment. A–F, H4-EGFP-
PRKN cells were pretreated for 30 min with Bay 11-7082, and the ubiquitination and degradation of the OMM proteins TOMM70 and RHOT2 were assessed by
Western blotting following CCCP treatment (10 M). A and D, representative Western blots showing 70-kDa TOMM70 (A) and 80-kDa RHOT2 (D) and higher-
molecular weight ubiquitinated species along with -tubulin loading control. B and E, quantification of the ubiquitinated species expressed as a fraction of the
total protein. C and F, quantification of total protein normalized to 0 M Bay 11-7082 and 0 h CCCP. Bay 11-7082 reduces CCCP-mediated ubiquitination of
TOMM70 and impairs its degradation. Bay 11-7082 also reduces CCCP-mediated ubiquitination of RHOT2, but the effect on its degradation is less clear. n  3
for all experiments. Lines, mean  S.D. (error bars). *, significant difference from 0-h CCCP at a given concentration of Bay 11-7082; #, significant difference
between highlighted pair; */#, p  0.05; **/##, p  0.01; ***, p  0.001.
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whereas measures based on the number of parkin puncta/cell
were not optimal for detecting parkin recruitment (Fig. 5, E–G).
Consistent with the results in H4-EGFP-PRKN cells, treatment
of SH-SY5Y-EGFP-PRKN cells with kenpaullone attenuated
parkin recruitment to the mitochondria following CCCP treat-
ment as measured by the total area of parkin puncta/cell
(F(3,8)  96.76, p  0.0001; Fig. 5F) and the intensity of EGFP-
PRKN within puncta compared with the cytoplasm (F(3,8) 
67.17, p  0.0001; Fig. 5G) without causing any cell toxicity (Fig.
S8C). In the absence of CCCP, kenpaullone had no effect on
PRKN puncta (Fig. 5, D–G).
To further investigate the effect of kenpaullone on mito-
chondria, we captured high-magnification (	40) images of
H4-EGFP-PRKN cells using an InCell Analyzer 2200 and seg-
mented the mitochondrial network using the organelle func-
tion (Fig. 6A). We were able to quantify CCCP-induced mito-
chondrial perinuclear clustering and fragmentation using the
InCell Work station measures “organelle - total area” and
“organelle - elongation” (Fig. 6, C and D). We also confirmed
that there was no cell death (Fig. S9A) and that parkin puncta
formed as expected (Fig. S9B). In the absence of CCCP, we
observed that kenpaullone increased the total area of the mito-
chondrial network (FCCCP(1,16)  73.22, p  0.0001; Fig. 6 (B
and C)). Pretreatment of kenpaullone prior to CCCP treatment
attenuated the CCCP-induced perinuclear clustering of mito-
chondria as measured by total area (Fken(3,16)  20.14, p 
0.0001; Fig. 6 (B and C)). Additionally, treatment with CCCP led
to fragmentation of the mitochondrial network, quantified by
an increase in the “elongation” measure (FCCCP(1,16)  335.5,
p  0.0001; Fig. 6D). Due to the nature of this measure, an
increased value corresponds to more circular objects, and
therefore the data show that CCCP caused the mitochondria to
become more fragmented. Again, pretreatment of kenpaullone
attenuated the effect of CCCP on mitochondrial fragmentation
(Fken(3,16)  12.79, p  0.001; Fig. 6D). We noted that the mea-
sures of the mitochondrial area in the 5 and 10 M kenpaullone
 CCCP cells were comparable with those in cells in the
absence of both compounds, suggesting that kenpaullone could
inhibit the effect of CCCP. To extend our findings, we differen-
tiated human fetal neuronal precursor cells (see supporting
Methods) to produce a heterogeneous population of neurons
and glia (Fig. S9C). When these differentiated cells were treated
with kenpaullone (5 M for 24 h) prior to labeling with Mito-
Tracker Red, we observed a dramatic increase in mitochondrial
Figure 6. Analysis of mitochondria in H4-EGFP-PRKN cells following treatment with CCCP, kenpaullone, and MPP. A, mitochondria stained with
MitoTracker Red CMX Ros imaged using the Cy3 channel on the INCell Analyzer 2200 (	40 objective). Segmentation overlay using the INCell Work station
software delineates nuclei (blue), cells (green), and mitochondria (yellow). Scale bar, 20 m. B, representative images of mitochondria in H4-EGFP-PRKN cells
treated with DMSO or kenpaullone (10 M) for 24 h, followed by 2-h CCCP (10 M) or vehicle control. Scale bar, 50 m. C, quantification of the total area of the
mitochondrial network/cell (n  3) showed a significant effect of both CCCP and kenpaullone (FCCCP(1,16)  73.22, p  0.0001; Fken(3,16)  20.14, p  0.0001). D,
quantification of the elongation of segmented mitochondria also showed a significant effect of both CCCP and kenpaullone. Note that greater values represent
more rounded objects (FCCCP(1,16)  335.5, p  0.0001; Fken(3,16)  12.79, p  0.001). E, treatment with 500 M MPP for 24 h resulted in significant reduction
in cytoplasmic MitoTracker Red staining intensity compared with control. There was a significant increase in cytoplasmic MitoTracker Red staining intensity in
MPP-treated cells in the presence of kenpaullone at 5 M compared with DMSO vehicle control (0 M kenpaullone) (n  3). F, cell count significantly
decreased in the presence of 500 M MPP compared with control. The addition of kenpaullone did not affect cell count in wells treated with 500 M MPP.
Lines, mean  S.D. (error bars). *, significant difference between DMSO and CCCP; #, significant difference between highlighted pair. */#, p  0.05; **/##, p  0.01;
***/###, p  0.001.
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staining (Fig. S9C), a result that is consistent with the results
observed in H4-EGFP-PRKN cells.
To further investigate the ability of kenpaullone to protect
mitochondria, we treated H4-EGFP-PRKN cells with the com-
plex I inhibitor MPP. In the absence of kenpaullone, 24-h
treatment with 500 M MPP reduced the uptake of Mito-
Tracker Red (p  0.05), indicating a reduction in m, and this
was accompanied by a reduction in cell number (p  0.001)
(Fig. 6, E and F). Co-treatment with kenpaullone (5 M) rescued
MitoTracker Red uptake (p  0.05), indicating that these cells
were able to maintain m, although there was no rescue of cell
death.
Our results suggest that kenpaullone inhibited or possibly
delayed the recruitment of parkin to mitochondria. To investi-
gate this, we used a microfluidics platform that allows for the
dynamic modulation of drug exposure with continuous moni-
toring of cell behavior (29 –31). We made single-cell measures
of parkin aggregation dynamics every 15 min for 6 h in
H4-EGFP-PRKN cells (Fig. S10A), which were continuously
perfused with medium containing CCCP (10 M) (Fig. 7). Fol-
lowing time-lapse experiments, images were processed for sin-
gle-cell EGFP-PRKN puncta quantification and cell tracking
(Fig. S10B; see “Experimental procedures” for details about
image processing and experimental set-up). H4-EGFP-PRKN
Figure 7. EGFP-PRKN puncta quantification under CCCP and/or kenpaullone regime. A and F, experimental scheme. H4-EGFP-PRKN cells were chip-
loaded 24 h prior to time-lapse start and cultured in a tissue culture incubator with constant perfusion with control (A) or kenpaullone-containing (F) medium.
The following day, the chip was placed on a widefield microscope, and cells were imaged every 15 min for 6 h, while constantly perfused with CCCP–
conditioned (A) or CCCP  kenpaullone– conditioned (F) medium. B–D and G–I, change in the number of PRKN puncta/cell over time (each trace represents an
individual cell). Cells were grouped according to the time of maximum EGFP-PRKN puncta formation, as represented by the shaded boxes. B and G, cells with
maximum PRKN puncta between 0 and 2 h; C and H, cells with maximum PRKN puncta between 2 and 4 h; D and I, cells with maximum PRKN puncta between
4 and 6 h; E and J, pie charts showing the distribution of the cells according to their EGFP-PRKN puncta peak. Lines in B–D and G–I, H4-EGFP-PRKN puncta
quantification of single cells.
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cells continuously perfused with CCCP-conditioned medium
were found to form EGFP-parkin puncta, as observed in our
plate-based assays (Fig. S10, B and C). To determine the dynam-
ics of the cellular response to CCCP exposure, we grouped cells
(tracked individually) based on the time window (0 –2, 2– 4,
4 – 6 h) in which the maximum number of EGFP-parkin puncta
was observed. Single cells equally distributed across three
groups, with 35% of cells peaking between 0 and 2 h, 30%
between 2 and 4 h, and 31% between 4 and 6 h (Fig. 7, B–E). We
then tested the effect of kenpaullone on EGFP-parkin puncta
formation. H4-EGFP-PRKN cells were perfused with kenpaul-
lone (5 M)-containing medium for 24 h before the start of the
experiment. During the time-lapse experiments, cells were con-
tinuously perfused with medium containing both CCCP and
kenpaullone (Fig. 7F). Tracking single cells and grouping them
as above, we found that EGFP-parkin puncta formation
occurred between 0 and 2 h in 18% of cells, whereas in the
majority (42% of cells), the peak was between 2 and 4 h; the
percentage of cells showing puncta between 4 and 6 h did not
change as compared with CCCP treatment only (Fig. 7, G–J). Of
note, in agreement with 96-well plate experiments (Fig. 5C), the
number of EGFP-parkin puncta was reduced when kenpaul-
lone was perfused in combination with CCCP (representative
image in Fig. S10 (C and D)). Indeed, the maximum -fold
increase in EGFP-parkin puncta in the presence of CCCP was
25 (Fig. 7, B–D), whereas, in the presence of kenpaullone, the
maximum -fold change was 15 (Fig. 7, G–I). These results dem-
onstrate the single-cell tracking and quantification of EGFP-
parkin puncta and the controlled delivery of drugs in living cells
and show that kenpaullone inhibits and delays parkin puncta
formation.
Discussion
We conducted a rigorous siRNA and drug screen to identify
(i) novel genes and pathways important in regulating parkin
recruitment and (ii) small neuroactive compounds and poten-
tial targets for therapeutic intervention in PD. We chose a
library composed of siRNAs targeting G protein– coupled
receptors, protein kinases, ion channels, phosphatases, pro-
teases, ubiquitin-conjugating enzymes, and genes involved with
apoptosis, senescence, nucleic acid binding, autophagy, DNA
repair, and characterized nuclear receptors.
We used a bioinformatic approach to explore the hit genes
and identified an overrepresentation of genes in the ubiquitin
proteasome pathway by PANTHER pathway analysis (protea-
some 26S subunit, ATPase 5 (PSMC5); proteasome 26S subunit,
ATPase 6 (PSMC6); UBE2L6; UBE2E1; and UBE2N). This clus-
ter was also revealed by STRING database analysis, which high-
lighted the interaction between the UBE2s UBE2E1, UBE2J2,
UBE2L6, and UBE2N; the UBE3s F-box and WD repeat domain
containing 12 (FBXW12) and ankyrin repeat and SOCS box–
containing 9 (ASB9); and the proteasome genes PSMC5,
PSMC6, and proteasome maturation protein (POMP). Ubiq-
uitination of parkin (itself a UBE3) and OMM proteins, includ-
ing mitofusin 1 (MFN1), mitofusin 2 (MFN2), Ras homolog
family member T1 (RHOT1/Miro1), TOMM70, and voltage-
dependent anion channel 1 (VDAC1), are known to be key steps
in the mitophagy pathway (32, 33). Therefore, the identification
of several UBE2s and UBE3s along with proteasomal subunits
highlights the importance of this pathway in mediating parkin
recruitment. UBE3s mediate the substrate specificity of the
ubiquitination reaction, determining not only the substrate
protein but also the type of ubiquitin linkage. UBE2s are
responsible for charging the UBE3 with ubiquitin monomers
and show specificity for specific UBE3s. UBE2s also confer
specificity to the type of linkage.
Of the four UBE2s identified here, two (UBE2N and UBE2J2)
showed a positive modulatory effect on parkin recruitment, and
two (UBE2L6 and UBE2E1) had a negative effect. This is in
agreement with, and adds to, the results of a previous study,
which demonstrated a positive role for UBE2N, ubiquitin-con-
jugating enzyme E2 L3 (UBE2L3), and ubiquitin-conjugating
enzyme E2 D2/3 (UBE2D2/3) in parkin translocation, ubiquiti-
nation, and degradation of OMM proteins and recruitment of
p62 to mitochondria and a negative role for ubiquitin-conjugat-
ing enzyme E2 R1 (UBE2R1) (28). A plausible interpretation of
these results is that UBE2s act as positive modulators to charge
parkin with Ub and/or facilitate the ubiquitination of sub-
strates, including parkin itself and OMM proteins. Existing evi-
dence suggests that UBE2N is primarily responsible for the
building of Lys-63–linked Ub chains (a linkage that is a well-
established method for directing cargo toward autophago-
some-mediated degradation rather than proteasomal) but is
less important for the initial charging of parkin with Ub (28, 34).
UBE2s that negatively regulate mitophagy may play a role in the
proteasomal degradation of cleaved PINK1; in this scenario,
their knockdown would promote PINK1 accumulation at the
mitochondria (35). In addition, there are additional mitochon-
drial resident UBE3s, such as mitochondrial E3 ubiquitin pro-
tein ligase 1 (MUL1), that play a role in mitophagy (36) and
whose activity would also be dependent on UBE2s and may be
modulated by the activity of recruited PINK1/parkin.
We observed a cooperative effect of the positive modulators
UBE2N and UBE2J2 on the recruitment of parkin to mitochon-
dria. This is in agreement with other studies that have shown
greater deficits when two or more UBE2s are knocked down
compared with knockdown of individual genes (34).
In addition to the UBE2 family members, two E3 ubiquitin
ligases (ASB9 and FBXW12) were included on our hit list. ASB9
has been shown to ubiquitinate mitochondrial creatine kinase
(CKMT1) and thus target it for degradation (37, 38). CKMT1 is
a gatekeeper of the mitochondrial permeability transition pore,
and loss of CKMT1 results in depolarization of mitochondria
and induction of apoptosis. The second UBE3 subunit we iden-
tified was FBXW12; this protein has not been well-character-
ized, but recently the rs9614 C variant has been associated with
a reduced risk of PD (39). Interestingly, alterations in both
ASB9 and FBXW12 have also been associated with Alzheimer’s
disease (40 –42). Current models of parkin recruitment suggest
the accumulation of PINK1 (on depolarized mitochondria)
mediates the phosphorylation of ubiquitin and parkin (19). This
basal activation then stimulates a feed-forward loop resulting in
further conjugation of ubiquitin to mitochondria and PRKN
recruitment. Hence, it is possible that ASB9 and FBXW12 play
a role in mediating the PINK1-mediated conjugation of ubiqui-
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tin to mitochondria and the subsequent amplification of parkin
recruitment.
Ubiquitination of proteins can target them for degradation
by the proteasome, and we identified two protease subunits
(PSMC5 and PSMC6) among our hit genes along with POMP.
Both PSMC5 and PSMC6 have been shown to interact with
parkin following CCCP-induced mitochondrial depolarization.
Furthermore, PSMC5 displayed parkin-dependent ubiquitina-
tion following CCCP treatment (33). In addition, PSMC6 has
been shown to interact with PINK1 (43). We also demonstrated
that inhibiting UBE2N with a pharmacological compound (Bay
11-7082) replicated the effects of the siRNA-mediated knock-
down both on PRKN recruitment and ubiquitination and deg-
radation of OMM proteins, further supporting a role for UBE2s
in mitophagy (i.e. subsequent to PINK1-parkin recruitment) via
the ubiquitination and degradation of OMM proteins.
Our analyses also identified a number of genes involved in
regulating cellular oxidative state as being able to modulate
PRKN recruitment. GSH reductase (GSR), a positive modulator
of parkin recruitment, was identified as a node gene by our
STRING database analysis. GSR catalyzes the reduction of
GSSG to GSH and so acts as an important antioxidant. Inter-
estingly, GSH peroxidase 6 (GPX6), which catalyzes the reverse
reaction, mainly oxidation of GSH to GSSG, was identified as a
negative modulator. Together, these hits strongly support a
positive role for GSH in parkin recruitment. Reduced GSH lev-
els in the substantia nigra have long been associated with PD
(44, 45), and although not thought to be a primary cause of the
disease, the decrease in GSH is hypothesized to exacerbate neu-
ronal damage, particularly by increasing oxidative stress (44).
GSH is one of most abundant cellular antioxidants. When GSH
levels are decreased, the cell struggles to remove reactive oxy-
gen species, resulting in increased reactive oxygen species levels
that lead to DNA damage, lipid peroxidation, and mitochon-
drial damage. Our analyses also found that genes involved in
regulating copper (SLC31A1, CP, and AOC1) and zinc metab-
olism (SLC30A4) regulated parkin recruitment (46). These
essential metals act as enzyme co-factors, and their dysregula-
tion has been shown to increase oxidative stress and activate the
SP1/AP1 and TGF- transcriptional pathways (46). Our screen
also identified transcription factors (SP1 and SNW1) involved
in regulating the SP1 and TGF- pathways. In addition, a num-
ber of genes known to regulate glucose metabolism (HK3, HK2,
and PPARG) were also found in our screen. Together, these
findings suggest that specific enzymatic, glucose, antioxidant,
and transcriptional systems impact the regulatory systems con-
trolling mitophagy, a simple explanation being that mitochon-
dria when not coping with additional stress (e.g. oxidative) have
more patent quality control systems.
In addition to the large druggable genome siRNA screen, we
conducted a screen of a small selected compound library. This
screen identified the CDK (specifically, CDK1, CDK2, and
CDK5) and glycogen synthase kinase (GSK3) inhibitor ken-
paullone as a negative modulator of parkin recruitment and
downstream mitophagy processes. Investigation of the mecha-
nisms underlying the inhibition of parkin revealed that in the
absence of CCCP, treating H4-EGFP-PRKN cells with kenpaul-
lone enlarged the area of the mitochondrial network. Further-
more, kenpaullone rescued the CCCP-induced perinuclear
clustering and fragmentation of mitochondria, therefore main-
taining a healthy network throughout the cytoplasm. Further
preliminary experiments showed that treatment with kenpaul-
lone dramatically increased the mitochondrial network in
human primary neurons and glia derived from fetal neuropro-
genitor cells. Kenpaullone may therefore be promoting healthy
mitochondrial dynamics and making them more resistant to
pathogenic change and/or stimulating mitochondrial biogene-
sis while repressing parkin recruitment. That the CDK-inhibi-
tory actions of kenpaullone may represent a therapeutic avenue
for PD is supported by recent data. CDK5 activation has been
implicated in PD; in particular, it has been found within Lewy
bodies and has been shown to mediate DA neurodegeneration
in mouse models of PD (47, 48). In the developing nervous
system, activation of CDK5 by p35 is important for neurite out-
growth and neuronal migration. However, cleavage of p35 by
calpains to p25 leads to aberrant activation of CDK5 and has
been associated with neurodegeneration in PD and Alzheimer’s
and Huntington’s diseases (49). More specifically with regard to
PD, p25/CDK5 has been demonstrated to regulate the ubiquitin
ligase activity of parkin via phosphorylation of serine 131 (50).
Additionally, CDK5 can regulate stress-induced autophagy via
phosphorylation of SH3 domain– containing GRB2-like, endo-
philin B1 (SH3GLB1/EndoB1/Bif1), which in turn recruits the
UVRAG/Beclin1complex(51).CDK1andCDK5alsophosphor-
ylate the PD-associated protein, vacuolar protein-sorting 34
(VPS34), inhibiting its interaction with Beclin1 and thus atten-
uating autophagy (52). Another major target of kenpaullone,
GSK3, has also been implicated in PD (53, 54), with polymor-
phisms in the GSK3 gene being associated with PD risk in the
East Asian population (55). Likewise, mitochondrial GSK3
exacerbates the effects of rotenone and MPP and increases
oxidative stress (54). Both CDK5 and GSK3 are negative reg-
ulators of the neuroprotective transcription factor myocyte
enhancer factor 2 (MEF2) (56). In addition to promoting neu-
ronal survival via transcription of nuclear genes, MEF2 can
localize to the mitochondria and regulate transcription of mito-
chondrial DNA– encoded genes as well as complex I activity
(57). Furthermore, MEF2 has been shown to be reduced in
mouse models of PD and post-mortem PD patient brain sam-
ples (57). She et al. (57) proposed that the loss of mitochondrial
MEF2 can sensitize neurons to toxic/stress insults and thus play
a role in the development of PD. Together, these reports sug-
gest synergistic mechanisms by which the inhibition of CDKs
and/or GSK3 by kenpaullone may alter parkin recruitment.
Overall, these findings suggest specific pathways and pharma-
cological compounds to be targeted and developed for the
treatment of PD.
Experimental procedures
Cell culture and generation of stable cell lines
H4 cells were used as they are of human origin and are
derived from a central nervous system tissue (neuroglioma);
additionally, they can be readily cultured, have high transfec-
tion efficiency, and are suitable for high-content imaging. H4
cells were maintained in Dulbecco’s modified Eagle’s medium
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(Sigma–Aldrich, D6546) supplemented with 10% fetal bovine
serum (Life Technologies, Inc., 10500064), 2 mM L-glutamine
(Sigma–Aldrich, G7513), and 5000 units/ml penicillin/10
g/ml streptomycin (Sigma–Aldrich, P4458). SH-SY5Y cells
were maintained in Dulbecco’s modified Eagle’s medium/F-12
(1:1) (Thermo Fisher Scientific, 21331020) supplemented with
10% fetal bovine serum (Life Technologies, 10500064), 2 mM
L-glutamine (Sigma–Aldrich, G7513), and 5000 units/ml peni-
cillin/10 g/ml streptomycin (Sigma–Aldrich, P4458). All cells
were maintained in a humidified incubator at 37 °C, 5% CO2.
H4 and SH-SY5Y cells stably expressing EGFP-PRKN were
created using a lentiviral vector. EGFP-PRKN (a kind gift from
Dr. Jon Lane, University of Bristol) was cloned into a third-
generation lentiviral backbone, and viral particles were pro-
duced by co-transfection of HEK293T cells as described previ-
ously (58). Cells were transduced with the virus and, after
repeated passaging, sorted by FACS to produce a cell line
expressing a consistent level of EGFP-PRKN.
EGFP-parkin mitochondrial recruitment assay for siRNA
screening
For the primary screen, the OnTarget Plus druggable
genome Smartpool siRNA (4 siRNAs/gene) library targeting
7500 genes (Thermo Fisher Scientific, G-104605) was used for
the primary screen. H4-EGFP-PRKN cells were seeded in
black-walled 96-well plates with optical bottoms (Corning,
3904) at a density of 4000 cells/well and 24 h later transfected
with 6 pmol of siRNA/well using Lipofectamine2000 (Thermo
Fisher Scientific, 11668019). An NTC smart pool (Thermo
Fisher Scientific, D-001810-10-50) was used to control for
transfection (wells A1, B1, C1, D1, E12, F12, G12, and H12), and
a PINK1-targeting smart pool was used as a positive control
(wells A12, B12, C12, D12, E1, F1, G1, and H1) (Thermo Fisher
Scientific, L-004030-00-0050). 48 h post-transfection, Mito-
Tracker Red CMXRos (100 nM; Thermo Fisher Scientific,
M7512) was added to label mitochondria. Mitophagy was
induced by adding 10 M CCCP (Sigma–Aldrich, C2759) for
2 h. Cells were fixed with 4% paraformaldehyde, and the nuclei
were labeled with Hoechst (1 g/ml). Transfections and assays
were performed in triplicate.
For the secondary screen, three individual Silencer Select
siRNAs (Ambion, Thermo Fisher Scientific) were used per
gene. An improved “controls” plate layout (59) involved the
repositioning of the NTC siRNA oligonucleotide (wells A2,
A12, C5, C8, D10, E3, F5, F8, H2, and H12) and PINK1-target-
ing siRNA oligonucleotide (wells A1, A11, C4, C9, F4, F9, H1,
and H11). 24 h after seeding, H4-EGFP-PRKN cells were trans-
fected with 0.25 pmol/siRNA well using Lipofectamine2000.
The assay was performed as for the primary screen except that
six replicate transfections and assays were performed for each
plate.
High-content imaging
Images were captured using an InCell Analyzer 1000 (GE
Healthcare). A 	10 objective was used, and four fields of view
were captured per well. The InCell Investigator software was
used to segment and quantify the images as follows. A top hat
algorithm was used to identify cell nuclei (Hoechst stain). Cell
boundaries were defined using a multiscale top hat algorithm
analysis on the MitoTracker Red CMXRos signal. Parkin
puncta were identified using the organelle feature with a mul-
tiscale top hat algorithm analysis of the EGFP signal. The out-
put of the InCell Investigator software for each plate consisted
of a set of tiff files of the images of the microscope taken at
different fields and a xls file with the associated numerical data.
The xls file included the data of the individual fields and also the
summary data of all of the fields and wells in different sheets.
The numerical data were recorded using 84 different parame-
ters as described in File S6. The initial primary screen data set
consisted of three replicates of 98 different plates. An additional
78 plates were analyzed after the quality control (QC) stage.
The secondary screen data set consisted of six replicates of 12
plates.
Data analysis workflows
The data were processed and analyzed using the open source
software R (60). For the data analysis, we used the well summary
data provided by the InCell Investigator software and three dif-
ferent workflows that take into account different parameter
selection approaches to compute a hit score for each gene: uni-
variate workflow, PCA workflow, and PLS workflow. These
three workflows can be summarized as having four parts each:
row/column artifact correction, quality control of the plates,
parameter selection, and hit selection. The only difference in
these workflows is in the parameter selection stage.
Row/column artifact correction
The preprocessing stage included a step aimed at reducing
the potential spatial artifacts that can arise in siRNA screenings
due to the geometry of the plates (59, 61). We applied the
method suggested by Zhang (59) to identify and correct these
systematic spatial artifacts. This method is based on a fitting
robust linear model for each plate, where the variable to be
corrected is fitted against the row and column numbers. If a
systematic effect exists in the plate, it will be captured in the
slope of such a model. The systematic artifacts are corrected by
removing the slope of the robust linear model from the data.
Quality control of the plates
To evaluate the quality of the plates and remove the ones that
contain unreliable data, we computed a robust plate-wise QC
score given by the following,
SSMDQC 
median








where MAD is the median absolute deviation, and it is defined
as follows.
MAD  1.4826  median
xij  median
 x (Eq. 2)
The indices i and j refer to the row and column of the well,
whereas the constant 1.4826 makes the MAD comparable with
the S.D. (62, 63). The SSMDQC cut-off value was set to 2, as
suggested for very strong positive controls (59). Therefore, all of
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the plates with an SSMDQC greater than 2 in the univariate
workflow were tagged as being of poor quality and were
removed from the data set.
Hit selection
We evaluated the effect of silencing a certain gene i for a
given variable by using a SSMD score per gene, which gives an
estimate of the effect of silencing a gene, compared with the







where s02 is the median of the squares of the S.D. values for all the
plate replicates, swell i2 is the square of the S.D. of the well i, and
welli is the readout of the ith well that we want to use to evaluate
whether the silenced gene in that well gives an output different
from the negative control wells (Control).
Description of the workflows
Three different strategies were followed to select the relevant
parameters that led to three different workflows for the data
analysis.
Univariate workflow—After row/column artifact compensa-
tion and the QC step, three parameters were selected as parkin
translocation indicators (Fig. S11). We performed this selection
according to previous literature, where it was shown that these
parameters are good readouts for PRKN translocation in siRNA
high-content screenings (20). These parameters were: percent-
age of cells with more than three parkin puncta, area of parkin
per cell, and parkin puncta/cell intensity. Each parameter was
fed to the robust SSMD formula, and a hit list for each param-
eter was obtained. We defined a threshold of SSMD  3 or
SSMD  3 to identify the hits.
PCA workflow—The row/column artifact compensation was
performed at the beginning of the workflow. We selected a sub-
set of six potential parameters that could be used as readouts for
parkin translocation. Through the plotting of the positive and
negative control data sets for these six parameters (Fig. S12), we
identified three that show a different pattern for positive and
negative controls and, therefore, could be used to evaluate the
level of parkin translocation. These parameters were percent-
age of cells with more than three parkin puncta, area of parkin
puncta per cell, and parkin puncta/cell intensity. This was fol-
lowed by QC and SSMD calculation for each of the three
parameters as described above. In the last step of the pipeline,
the three SSMD values per gene were combined using a PCA
model to extract the main source of variance in the data and
reduce the dimensionality to just one parameter per gene as
follows.
X was defined as a matrix having as many rows as the number
of genes screened and three columns (one for each of the
selected parameters in this workflow). Application of a singular
value decomposition generated the following,
X  UDVT (Eq. 4)
where U and V were the left and right singular vectors, respec-
tively, and D was a diagonal matrix with the corresponding
singular values. Rearrangement of this equation resulted in the
generation of a metric for PCA decomposition,
X  HWT  E (Eq. 5)
where W was the loading matrix, H was the scores matrix, and
E was the residual matrix. The dimensionality of the H and W
matrices depends on the number of latent components that are
assumed to be playing a role in the variance of the data. In our
case, it was assumed that there was only one component cap-
turing the differences between the positive and negative con-
trols and, therefore, the matrix H only had one column and as
many rows as genes. We used each of the scores in the vector H
as a consensus SSMD value (PCAscore) that combined the
three SSMD scores computed in the previous steps. A threshold
was set at SSMD  3 or SSMD  3 to obtain the list of hits in
the primary screen. The secondary screen consisted of three
nonpooled different siRNAs targeting the candidate genes.
This caused a drop in the effect sizes of the readouts that led us
to set a significance threshold for the secondary screening of
SSMD  1.3 or SSMD  1.3.
PLS workflow—The PLS workflow was the most parameter-
agnostic of the workflows that we applied, as it lacked manual
selection of parameters. The correlation structure of the initial
screening data shows groups of variables that are highly corre-
lated (Fig. S12). The first step of this workflow was the row/
column compensation step. The next step in the workflow
involved the detection of outliers, which was based on Hotell-
ing’s T2 for control values. To perform a first selection of rele-
vant features, a t test for each parameter was performed using
the positive and negative control data. At a false discovery rate
cut-off of 0.05, we found that 65 of the 84 parameters were
significant. These were used to build a PLS model using the
control data.
Given a set of M variables measured for N samples
expressed as a data matrix X and the readouts of L observa-
tions for the same N samples in another data matrix Y, PLS
performed a decomposition of both matrices,
X  TPT  E (Eq. 6)
Y  UQT  F (Eq. 7)
where T and U were the X-scores and Y-scores, respectively, P
and Q were the X-loadings and Y-loadings, and E and F were the
X-residuals and Y-residuals. The decomposition was computed
so that the covariance between T and U was maximized. In this
case, the matrix with the readouts of the 65 parameters for the
control wells was matrix X, and matrix Y was the matrix con-
taining the labels of the controls (NTC or PINK1). We fitted
this model using cross-validation to avoid overfitting and used
it to predict scores for the noncontrol wells. These scores were
fed to the QC stage as described above to remove misleading
plates. The data of the plates that passed were used to build
another PLS model. The scores of this PLS model were used as
welli in the hit selection step as described above. Finally, we set
a threshold at SSMD  3 or SSMD  3 to obtain the list of hits
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in the primary screen. The secondary screening consisted of
three nonpooled different siRNAs targeting the candidate
genes. This caused a drop in the effect sizes of the readouts,
resulting in the significance threshold for the secondary screen-
ing being set to SSMD  1.3 or SSMD  1.3.
Gene expression in H4 cells
To extract the list of genes that were expressed in H4 cells, we
queried the Gene Expression Omnibus (https://www.ncbi.nlm.
nih.gov/geo/) for control H4 cells. Eight samples were identi-
fied that fulfilled these conditions, and these samples were
downloaded. The GEO IDs of the samples were GSM203-
415, GSM203416, GSM203417, GSM549595, GSM887031,
GSM1050692, GSM1050693, and GSM1050694. An extra three
samples were downloaded from Array Express (https://www.
ebi.ac.uk/arrayexpress/)3 (68). The sample IDs for these sam-
ples were H4_SS331525_HG-U133_Plus_2_HCHP-167398,
H4_SS331526_HG-U133_Plus_2_HCHP-167399, and H4_SS-
331527_HG-U133_Plus_2_HCHP-167400. These files were
analyzed using the expresso function of the affy package in R
(64). We used RMA to correct the background and quantile
normalization and median polish as a method to summarize the
probes. The probability density of the data had a bimodal shape
due to the mixture of expressed and nonexpressed genes. To
deconvolute both distributions, we fitted a Gaussian mixture
model made of two Gaussian distributions using expectation
maximization and the R package mclust (65, 66).
The Gaussian with the lower mean value corresponded to the
nonexpressed distribution, whereas the Gaussian distribution
with the higher mean corresponded to the distribution of
expressed genes. We sampled 10,000 points from the distribu-
tion of nonexpressed genes, and we computed gene-wise t tests
between the expression of the genes and these sampled points.
The p values of such tests were corrected by multiple testing.
The genes whose corrected p values were under or equal to 0.05
were considered not to have been generated from the distribu-
tion of nonexpressed genes. As a gene is either expressed or
nonexpressed (there are only two distributions originating the
data, given that all of the samples are H4 controls), the signifi-
cant genes of such tests were considered as expressed genes.
The rest of the genes were considered nonexpressed in the H4
cell line.
Parkin interactor enrichment
To evaluate whether the list of hits that were identified out of
the primary screening were enriched for parkin interactors, a
hypergeometric test using a list of genes previously reported to
be interactors of parkin was performed (24).
qPCR validation of siRNA knockdown
H4-EGFP-PRKN cells were seeded in 12-well plates at a den-
sity of 50,000 cells/well. Cells were transfected with 3 pmol of
siRNA/well using Lipofectamine2000 (2 l/well). 48 h post-
transfection, RNA was extracted using the ReliaPrepTM RNA
Cell and Tissue Miniprep Systems (Promega, Z6212). 1 g of
RNA was reverse-transcribed to cDNA using the High-Capac-
ity cDNA Reverse Transcription Kit (Thermo Fisher Scientific,
4368814). To assess the degree of mRNA knockdown, qPCR
was performed using Power SYBR Green PCR Master Mix
(Thermo Fisher Scientific, 4367659) and specific primers (300
nM) (File S7). All transfections were performed in triplicate, and
three technical replicates of each PCR were run. Data were ana-
lyzed using the Ct method with -actin serving as the endog-
enous control and NTC transfection as the normalizer.
Parkin recruitment assays
These individual assays were performed in an identical man-
ner to those for the primary and secondary screens. For these
siRNA experiments, H4-EGFP-PRKN or SH-SY5y-EGFP-
PRKN cells were seeded in black-walled 96-well plates and
transfected with siRNAs for 48 h. They were then labeled with
MitoTracker Red CMXRos and treated with CCCP (10 M) for
2 h, followed by fixation and Hoechst staining. For pharmaco-
logical compound experiments, cells were pretreated with the
compound prior to CCCP treatment in the continued presence
of the compound. Stock solutions of Bay 11-7082 (Sigma–
Aldrich, B5556, 25 mM) and kenpaullone (Sigma–Aldrich,
K3888, 5 mM) were prepared in DMSO, and serial dilutions
were prepared in medium. Plates were imaged and quantified
using the InCell Analyzer as described above.
Western blotting
To assess the ubiquitination of OMM proteins, H4-EGFP-
PRKN cells were seeded in 12-well plates at a density of 55,000
cells/well. 48 h post-transfection, mitochondrial recruitment of
EGFP-parkin was induced by treatment with CCCP (10 M).
For pharmacological compound experiments, these cells were
pretreated with the compound (see “Parkin recruitment
assays”) prior to CCCP (10 M) treatment in the continued
presence of the indicated compound. Cells were lysed in radio-
immune precipitation assay buffer, and the protein concentra-
tions were determined using a BCA assay (Thermo Fisher Sci-
entific). Typically, 20 g of protein was mixed with SDS sample
buffer, heat-denatured, and loaded onto 10% polyacrylamide
gels followed by electrophoresis in a Tris-glycine buffer. Pro-
teins were transferred to a polyvinylidene difluoride mem-
brane, which was subsequently blocked with 5% milk powder in
PBS and probed with primary antibodies against TOMM70
(Proteintech 14528-1-AP; 1:500 in 1% milk PBS), RHOT2 (Pro-
teintech 11237–1-AP; 1:500 in 1% milk PBS), and -tubulin
(Sigma T5168; 1:2000 in 1% milk PBS). Blots were then probed
with species-specific horseradish peroxidase– conjugated sec-
ondary antibodies (Amersham Biosciences, NA931/NA934)
before development with enhanced chemiluminescence
(TOMM70 and RHOT2: ECL Prime GE Healthcare, RPN2232;
-tubulin Thermo Scientific SuperSignal West Pico, 34580).
ImageJ (National Institutes of Health) densitometry was used to
measure semi-quantifiably the expression of each protein.
Expression of native and ubiquitinated forms were normalized
to that of -tubulin, and the ratio of ubiquitinated to total pro-
tein was calculated.
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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A library of neuroactive compounds was selected and a mas-
ter plate (96-well) was prepared containing a 5 mM compound
of each compound (in DMSO). Compounds were stamped into
daughter plates and diluted to 50 M with culture medium. This
was then further diluted 1:5 by the addition of 25 l to cells
seeded in 100 l of medium 96-well plates, giving a final con-
centration of 10 M and final DMSO concentration of 0.2%.
Cells were incubated with the compounds for 24 h prior to
CCCP treatment (10 M, 2 h) in the continued presence of 10
M compound. Cells were fixed and Hoechst-stained, and
plates were imaged and quantified using the InCell Analyzer as
described above. Compounds that reduced cell number by
20% were excluded from analysis of parkin puncta.
Mitochondrial network analysis
To image and analyze the mitochondrial network, H4-EGFP-
PRKN cells were seeded in black-walled 96-well plates with
optical bottoms (Greiner, 655090). Cells were treated with ken-
paullone or vehicle control for 24 h prior to loading with Mito-
Tracker Red CMXRos and treatment with CCCP. Images were
captured on an InCell Analyzer 2200 using the 	40 objective
and two-dimensional deconvolution mode. The InCell Investi-
gator software was used to segment and quantify the images as
follows. A top hat algorithm was used to identify cell nuclei
(Hoechst stain). Cell boundaries were defined using a multi-
scale top hat algorithm analysis on the MitoTracker Red
CMXRos signal. Mitochondria were identified using the organ-
elle feature with a multiscale top hat algorithm analysis of the
MitoTracker Red CMXRos signal.
Microfluidics/microscopy-based time lapses
Microfluidics time lapses were performed using the device
designed in the laboratory of Prof. Jeff Hasty (University Cali-
fornia San Diego, La Jolla, CA) (67) and optimized for mamma-
lian cell growth, ensuring controlled flow perfusion, CO2 diffu-
sion, and minimal stress. Pelleted cells from a subconfluent
75-cm flask were resuspended in 500 l of complete medium
and chip-loaded as in Ref. 30. Cells were cultured for 24 h in a
tissue culture incubator (5% CO2, 37 °C) under constant perfu-
sion with standard or kenpaullone-containing medium.
Medium was perfused with a syringe directly connected to port
2 via 24-gauge PTFE tubing (Cole-Parmer Inc.). Port 5 was used
for waste medium, whereas ports 1, 6, and 7 were plugged to
avoid medium spillage. The day after, the device was perfused
with medium containing the nuclear dye Hoechst (1 M) for 30
min before being transferred onto the widefield microscope for
the time lapse. The actuation system consists of two motor-
controlled syringes (http://biodynamics.ucsd.edu/dialawave/)3
connected to ports 6 and 7. One syringe contained standard
medium, and the second contained either CCCP– or CCCP 
kenpaullone–supplemented medium. Ports 1, 2, and 5 are also
connected to static syringes working as waste tanks. The cor-
rect flow of the medium was measured using a red dye
(sulforhodamine 101 from Sigma) added to the CCCP/
kenpaullone– containing syringe.
The microscopy platform consisted of a Leica DMi8 inverted
microscope equipped with the digital camera Andor iXON 897
ultra back-illuminated EMCCD (512 	 512, 16-m pixels,
16-bit, 56 fps at full frame) and an environmental control cham-
ber (PeCon) for long-term temperature control and CO2
enrichment. The adaptive focus control ensures that the focus
is maintained during the entire time-course experiment. The
experimental set-up includes consecutive acquisition in three
channels (phase-contrast and green and red fluorescence) with
a 	40 objective every 15 min. A power lamp was set at 33% with
an exposure time of 500 ms.
Microfluidics/microscopy image segmentation
Single cells were segmented using an image-processing algo-
rithm recognizing the nucleus, in the blue spectrum (Hoechst),
as an ellipse by means of the MATLAB function regionprops
(Mathworks Matlab R2018b).
For puncta identification, we first designed a threshold in the
green spectrum (EGFP-parkin) to generate a binary image
selecting only pixels belonging to EGFP-parkin puncta by using
the MATLAB function imextendmax (Mathworks Matlab
R2018b); then we selected a threshold on puncta area size (5 
area  2000). Finally, identified EGFP-parkin puncta were
attributed to the cell they belong to by measuring the relative
distance of the EGFP-parkin puncta centroid to the nucleus
center. For cell attribution, puncta centroid distance from the
nucleus center has to be less than or equal to the nucleus diam-
eter. A summary of the segmentation pipeline is shown in Fig.
S8B.
Statistical analysis
Experimental data were analyzed in GraphPad Prism by one-
way or two-way analysis of variance as appropriate with post
hoc tests. F values are reported as Fcondition(x,y), where x repre-
sents the condition degrees of freedom and y is the error
degrees of freedom.
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